FY2024 EPS Estimates for QNRX Decreased by Zacks Small Cap

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) – Research analysts at Zacks Small Cap cut their FY2024 earnings per share (EPS) estimates for shares of Quoin Pharmaceuticals in a research report issued to clients and investors on Tuesday, November 12th. Zacks Small Cap analyst M. Marin now forecasts that the company will post earnings of ($2.05) per share for the year, down from their prior estimate of ($2.02). The consensus estimate for Quoin Pharmaceuticals’ current full-year earnings is ($2.02) per share. Zacks Small Cap also issued estimates for Quoin Pharmaceuticals’ FY2025 earnings at ($2.00) EPS.

Quoin Pharmaceuticals Price Performance

QNRX stock opened at $0.61 on Thursday. Quoin Pharmaceuticals has a one year low of $0.48 and a one year high of $6.18. The stock has a market cap of $3.07 million, a price-to-earnings ratio of -0.15 and a beta of 1.85. The company has a fifty day moving average price of $0.65 and a two-hundred day moving average price of $0.65.

Institutional Trading of Quoin Pharmaceuticals

A hedge fund recently bought a new stake in Quoin Pharmaceuticals stock. Virtu Financial LLC acquired a new position in shares of Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 30,749 shares of the company’s stock, valued at approximately $29,000. Virtu Financial LLC owned about 0.77% of Quoin Pharmaceuticals as of its most recent SEC filing. Institutional investors and hedge funds own 8.63% of the company’s stock.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.